Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ESSA Pharma Inc. is a clinical-stage biotechnology company focused on developing novel therapies for prostate cancer. Its proprietary small molecule inhibitors target the androgen receptor's N-terminal domain to overcome resistance mechanisms. The company’s lead candidate, masofaniten (EPI-7386), was designed to treat advanced prostate cancer, often in combination with existing antiandrogens. ESSA aims to improve androgen suppression and delay drug resistance in AR-driven prostate cancer.
This description was generated via AI from an annual report. Updated about 1 year ago.